AveXis Inc (NASDAQ:AVXS) had its price target upped by stock analysts at Jefferies Group LLC from $79.00 to $92.00 in a note issued to investors on Friday. The firm presently has a “buy” rating on the stock. Jefferies Group LLC’s target price points to a potential upside of 15.36% from the company’s current price.
Several other research firms have also recently weighed in on AVXS. Zacks Investment Research cut shares of AveXis from a “hold” rating to a “sell” rating in a research report on Friday, January 13th. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price objective (up previously from $85.00) on shares of AveXis in a research report on Tuesday, February 7th. BMO Capital Markets reaffirmed an “outperform” rating and set a $95.00 price objective (up previously from $85.00) on shares of AveXis in a research report on Friday. Finally, Goldman Sachs Group Inc upped their price objective on shares of AveXis from $91.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $85.33.
Shares of AveXis (NASDAQ:AVXS) opened at 79.75 on Friday. AveXis has a 12 month low of $20.51 and a 12 month high of $85.98. The stock’s 50 day moving average is $62.69 and its 200 day moving average is $53.26. The firm’s market cap is $2.21 billion.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, March 16th. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by $0.12. During the same period last year, the company earned ($1.82) EPS. Analysts forecast that AveXis will post ($3.93) EPS for the current fiscal year.
var userip;Your IP Address: document.write(userip);
Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC boosted its stake in shares of AveXis by 67.6% in the fourth quarter. FMR LLC now owns 4,151,443 shares of the company’s stock worth $198,148,000 after buying an additional 1,674,424 shares in the last quarter. RA Capital Management LLC boosted its stake in shares of AveXis by 29.3% in the third quarter. RA Capital Management LLC now owns 1,732,274 shares of the company’s stock worth $71,387,000 after buying an additional 392,892 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of AveXis by 5.8% in the fourth quarter. Franklin Resources Inc. now owns 1,196,960 shares of the company’s stock worth $57,131,000 after buying an additional 65,550 shares in the last quarter. Boxer Capital LLC boosted its stake in shares of AveXis by 243.2% in the fourth quarter. Boxer Capital LLC now owns 1,028,763 shares of the company’s stock worth $49,103,000 after buying an additional 729,007 shares in the last quarter. Finally, RTW Investments LP boosted its stake in shares of AveXis by 2.8% in the fourth quarter. RTW Investments LP now owns 849,043 shares of the company’s stock worth $40,525,000 after buying an additional 23,063 shares in the last quarter. 68.31% of the stock is owned by hedge funds and other institutional investors.
AveXis Company Profile
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.